Market Access 2020: Understanding US Payer Expectations
How Much Longer For Biopharma’s Habitual Hamlet Fixation: To Risk Or Not To Risk?
Executive Summary
Big pharma is facing a difficult US competitive landscape as its traditional customers realign to build their own redoubts of size, scale and reach.
You may also be interested in...
Lilly's Bridge Builder, From Indiana To South Africa
Rising Leader Christopher Jon Stokes of Eli Lilly explains how some early life lessons in the restorative powers of community has guided a distinctive career path marked by engaging widely, understanding intuitively and listening actively, all in the pursuit of forging productive human connections that strive to “meet the moment” for patients.
Africa’s Geographer Of Genes
Nigerian start-up 54gene seeks to be the first private sector enterprise bent on applying Africa’s rich genetic heritage to solve the world’s most intractable diseases – ethically, without boundaries, for all.
The Medicines Patent Pool Plots A Post-Pandemic Future: Interview With Director Charles Gore
As the global access debate adapts to the stark inequities exposed by the COVID-19 pandemic, the UN-backed Medicines Patent Pool is emerging as a key player on issues ranging from vaccine tech transfer to making more drugs affordable against the spread of non-communicable diseases like cancer to middle- and low-income countries.